6 investors discuss why AI is more than just a buzzword in biotech
TechCrunch
DECEMBER 15, 2022
“Most of the companies we have seen have an AI component to support the discovery or development processes,” Francisco Dopazo, a general partner at Humboldt Fund told TechCrunch recently. The survey also covers the implications of U.S As a result, a significant proportion of biotech companies are trading below cash.
Let's personalize your content